Nanjing HuaNuo Bio-Pharmaceutical Technology

Nanjing HuaNuo Bio-Pharmaceutical Technology is a clinical-stage biotechnology company based in Nanjing, China, specializing in the discovery and development of innovative peptide-based therapeutics. The company focuses primarily on metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Its core technology platform enables the design of multi-target agonists, such as GLP-1/GIP dual agonists and GLP-1/GIP/GCG triple agonists. Nanjing HuaNuo aims to provide next-generation treatments with improved efficacy and safety profiles compared to existing metabolic therapies. The company has successfully advanced several candidates into clinical trials and continues to expand its pipeline through internal R&D.